Oral administration of Saccharomyces cerevisiae UFMG A-905 prevents allergic asthma in mice.
The prevalence of asthma has increased in communities that adopt a Western lifestyle and become more urbanized. Probiotics may be effective in the prevention of allergic diseases, such as asthma. The aim of the current study was to examine the effects of Saccharomyces cerevisiae UFMG A-905 in an allergic model of asthma.



Balb/c mice were sensitized twice with ovalbumin (OVA) intraperitoneally, 1 week apart and challenged with OVA intranasally for 3 days. Mice were daily treated with S. cerevisiae UFMG A-905 via gavaging needle 10 days before OVA sensitization and during challenges. After challenge, in vivo lung function was measured, and bronchoalveolar lavage (BAL) and lung inflammation were assessed.



Oral treatment with S. cerevisiae UFMG A-905 significantly decreased airway hyperresponsiveness, total cell number and the influx of eosinophils to the airway, inflammatory cell in the lung, mucus expression in epithelial cells and the levels of IL-4, IL-5 and IL-13. Additionally, S. cerevisiae UFMG A-905 restored the levels of IL-10 and interferon (IFN)-gamma, and increased the levels of IL-17A.



Oral administration of S. cerevisiae UFMG A-905 prevented the development of major asthma-like characteristics in a mouse model.
Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Vanessa M B
VMB
Fonseca
Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Thamires M S
TMS
Milani
Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Rafael
R
Prado
Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Vania L D
VLD
Bonato
Department of Pathology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Simone G
SG
Ramos
Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Flaviano S
FS
Martins
Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Elcio O
EO
Vianna
Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Marcos de C
MC
Borges
D000284:Administration, Oral; D000818:Animals; D001249:Asthma / Q000276:immunology* / Q000517:prevention & control; D001992:Bronchoalveolar Lavage Fluid; D004195:Disease Models, Animal; D004804:Eosinophils / Q000276:immunology; D007371:Interferon-gamma / Q000276:immunology; D016753:Interleukin-10 / Q000276:immunology; D018793:Interleukin-13 / Q000276:immunology; D020381:Interleukin-17 / Q000276:immunology; D015847:Interleukin-4 / Q000276:immunology; D008168:Lung / Q000276:immunology / Q000503:physiopathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin; D019936:Probiotics; D012130:Respiratory Hypersensitivity / Q000276:immunology* / Q000517:prevention & control; D012441:Saccharomyces cerevisiae
D018793:Interleukin-13; D020381:Interleukin-17; D016753:Interleukin-10; D015847:Interleukin-4; D007371:Interferon-gamma; D010047:Ovalbumin

Saccharomyces cerevisiae
; animal models; inflammation; primary prevention; probiotics